A strategic pharmacoepidemiology executive with a proven track record of designing and executing go-to-market strategies for the Life Sciences sector. Michael is an expert in architecting innovative real-world evidence solutions and commercial prospecting, deeply embedding advanced analytics into both the drug development life cycle as well as in sales model to drive organizational growth.

His unique insight combines a deep understanding of the global regulatory landscape—shaping integrated evidence strategies for the regulatory bodies—with the application of AI-augmented approaches to identify market opportunities and deliver scientifically robust evidence that meets commercial and access objectives.